These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 6186164)

  • 1. Serum drug concentrations in patients with ischemic heart disease after administration of a sustained release procainamide preparation.
    Zema MJ; Mirando T
    Angiology; 1983 Jan; 34(1):32-9. PubMed ID: 6186164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Steady-state plasma and saliva concentrations of procainamide and N-acetyl-procainamide after a sustained release preparation].
    Pirovino M; Karlaganis G; Galeazzi RL
    Schweiz Med Wochenschr; 1980 Sep; 110(39):1415-9. PubMed ID: 6169144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic comparisons of twice daily and four times daily formulations of procainamide in patients with frequent ventricular premature depolarization.
    Yang BB; Abel RB; Uprichard AC; Smithers JA; Forgue ST
    J Clin Pharmacol; 1996 Jul; 36(7):623-33. PubMed ID: 8844445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion from intravenous procainamide to oral sustained release tablets in cardiac patients.
    Kalin ML; Babich MF; Klinke WP; Hui WK
    Can J Cardiol; 1990; 6(1):15-8. PubMed ID: 2310989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Verification of therapeutic levels of procainamide and N-acetyl- procainamide in ventricular arrhythmia].
    Sinkiewicz W; Marzec A; Jankowski A; Hoffmann A; Makuch K; Romański B
    Pol Tyg Lek; 1990 Jun 4-11; 45(23-24):458-60. PubMed ID: 1703654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, plasma concentrations and adverse effects of a new sustained release procainamide preparation.
    Giardina EG; Fenster PE; Bigger JT; Mayersohn M; Perrier D; Marcus FI
    Am J Cardiol; 1980 Nov; 46(5):855-62. PubMed ID: 6159783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-acetylprocainamide's antiarrhythmic action in patients with ventricular tachycardia.
    Somberg J; Wynn J; Miura D; Torres V; Williams S; Keefe D
    Angiology; 1986 Dec; 37(12 Pt 2):972-81. PubMed ID: 2433972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative bioavailability of two oral sustained-release procainamide products.
    Baker BA; Reynolds JR; Gleckel L; A'Zary E; Bodenheimer MM
    Clin Pharm; 1988 Feb; 7(2):135-8. PubMed ID: 3349748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electrophysiologic comparative study of procainamide and N-acetylprocainamide in anesthetized dogs: concentration-response relationships.
    Jaillon P; Winkle RA
    Circulation; 1979 Dec; 60(6):1385-94. PubMed ID: 91451
    [No Abstract]   [Full Text] [Related]  

  • 10. High performance liquid chromatography of procainamide and N-acetylprocainamide in human blood plasma.
    Raphanaud D; Borensztejn M; Dupeyron JP; Guyon F
    Ther Drug Monit; 1986; 8(3):365-7. PubMed ID: 2428144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrophysiologic evaluation of the antiarrhythmic effects of N-acetylprocainamide for ventricular tachycardia secondary to coronary artery disease.
    Wynn J; Miura DS; Torres V; Flowers D; Keefe D; Williams S; Somberg JC
    Am J Cardiol; 1985 Nov; 56(13):877-81. PubMed ID: 2414983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous N-acetylprocainamide disposition kinetics in coronary artery disease.
    Kates RE; Jaillon P; Rubenson DS; Winkle RA
    Clin Pharmacol Ther; 1980 Jul; 28(1):52-7. PubMed ID: 6156049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide.
    Vlasses PH; Kosoglou T; Chase SL; Greenspon AJ; Lottes S; Andress E; Ferguson RK; Rocci ML
    Arch Intern Med; 1989 Jun; 149(6):1350-3. PubMed ID: 2471472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide.
    Roden DM; Reele SB; Higgins SB; Wilkinson GR; Smith RF; Oates JA; Woosley RL
    Am J Cardiol; 1980 Sep; 46(3):463-8. PubMed ID: 6158263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum drug concentrations and adverse effects in cardiac patients after administration of a new controlled-release disopyramide preparation.
    Zema MJ
    Ther Drug Monit; 1984; 6(2):192-8. PubMed ID: 6740739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative bioequivalence and efficacy of two sustained-release procainamide formulations in patients with cardiac arrhythmias.
    Hilleman DE; Patterson AJ; Mohiuddin SM; Ortmeier BG; Destache CJ
    Drug Intell Clin Pharm; 1988; 22(7-8):554-8. PubMed ID: 2458219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of age, gender, and race on steady state procainamide pharmacokinetics after administration of procanbid sustained-release tablets.
    Koup JR; Abel RB; Smithers JA; Eldon MA; de Vries TM
    Ther Drug Monit; 1998 Feb; 20(1):73-7. PubMed ID: 9485559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical pharmacology and antiarrhythmic efficacy of acetylprocainamide in patients with arrhythmias.
    Kluger J; Drayer D; Reidenberg M; Ellis G; Lloyd V; Tyberg T; Hayes J
    Am J Cardiol; 1980 Jun; 45(6):1250-7. PubMed ID: 6155064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained-release procainamide: use of serum concentrations to determine dosage.
    Reed WE; Cooper MW
    South Med J; 1985 Oct; 78(10):1190-3. PubMed ID: 4049036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme immunoassay, liquid chromatography, and spectrofluorometry compared for the determination of procainamide and N-acetylprocainamide in serum.
    Pape BE
    J Anal Toxicol; 1982; 6(1):44-8. PubMed ID: 6176781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.